Not the criminal you paint him to be.....in fact, just the opposite:
Mr. Joseph S. Podolski, also known as Joe, served as the Chief Executive Officer of Repros Therapeutics Inc. from 1992 to February 1, 2017 and also served as its President until February 1, 2017. Mr. Podolski served as the Vice President of Operations at Repros Therapeutics Inc. (formerly Zonagen, Inc.) since joining 1989. He previously served as its President of Repros Therapeutics Inc. from 1992 to February 2009. Prior to joining Repros Therapeutics Inc., he spent twelve years in various engineering, product development and manufacturing positions at G.D. Searle, a subsidiary of Monsanto Company. Before joining Monsanto, Mr. Podolski held positions in manufacturing, engineering, quality control and development of fine chemicals, antibiotics, pharmaceuticals and hospital products with Abbott Laboratories, Dearborn Chemical Company and Baxter Pharmaceuticals. Mr. Podolski has over 36 years experience in the pharmaceutical and biotech industry. He serves as a Board Member of Oncolix Inc. He served as a Director of Repros Therapeutics Inc. from 1992 to February 1, 2017. He has an in-depth working knowledge of the process surrounding intellectual property evolution. He is a named as the inventor on thirteen issued US patents and numerous applications and concepts. He is named as the inventor of the technology surrounding the company's Androxal Program and two of the second generation impotence therapies and championed the efforts leading to the licensing of the NIH selective progesterone receptor modulators. Mr. Podolski holds a B.S. degree in chemistry and an M.S. degree in chemical engineering from the Illinois Institute of Technology.
